USDJPY stays in a upward price channel

USDJPY stays in a upward price channel on 4-hour chart, and remains in uptrend from 95.81, the price action from 100.22 is treated as consolidation of the uptrend. Initial support is at 98.75, as long as this level holds, the uptrend could be expected to resume, and one more rise to 101.50 area is still possible. Key support is at the lower line of the channel, only a clear break below the channel support will indicate that the upward movement is complete, then the following downward movement could bring price to 95.00 zone.

usdjpy

Provided by ForexCycle.com

Griffin Securities’ Keith Markey Gives Performance Reviews on Four Favorite Biotech Names

Source: Peter Byrne of The Life Sciences Report (9/12/13)

http://www.thelifesciencesreport.com/pub/na/griffin-securities-keith-markey-gives-performance-review-on-four-top-biotech-names

As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss.

The Life Sciences Report: In your last interview withThe Life Sciences Report in March, you revealed your best ideas in biotech research. Where do you stand on those names now?

Keith Markey: I am quite pleased with the performance of the four companies that I mentioned:MannKind Corp. (MNKD:NASDAQ), Oragenics Inc. (OGEN:OTCBB), Synthetic Biologics Inc. (SYN:NYSE.MKT) and RXi Pharmaceuticals Corp. (RXII:OTCQX).

Mannkind Corp. recently reported the outcomes of two phase 3 clinical trials investigating the safety and efficacy of its inhalable insulin, Afrezza. The company’s novel delivery technology enables the drug to mimic the normal physiological release of insulin by the pancreas upon consumption of a meal. The Affinity 1 trial enrolled 518 type 1 diabetic patients, who received a basal insulin and either Afrezza or a short-acting insulin analog, NovoLog (Novo Nordisk [NVO:NYSE]). The Afrezza patients were then subdivided to allow comparison of an inhaler that had been used in virtually all of Mannkind’s trials with a new, smaller inhaler that the company will commercialize. The Affinity 2 trial enrolled 353 type 2 diabetics whose disease was inadequately controlled by oral medications. The results of both studies were quite good.

The type 1 trial was set up to prove noninferiority relative to the short-acting insulin analog, and to demonstrate that the two different inhalers operate equivalently. The results showed noninferiority of the insulin analog and comparable performance by the two inhaler devices. Mannkind needed these positive results to get approval for Afrezza from the U.S. Food and Drug Administration (FDA).

The type 2 trial was designed to demonstrate that when Afrezza is added to a regimen of oral medications for diabetics, it improves glycemic control in patients who are no longer fully responsive to the oral medications. Not surprisingly, insulin works. I say it that way because insulin is a hormone. It is not a novel drug—but the Mannkind delivery mechanism is novel.

TLSR: Is Afrezza easy to use?

KM: It’s fantastically easy. Here is the backstory. Some years ago, Pfizer Inc. (PFE:NYSE) attempted to commercialize an inhalable insulin, but it didn’t work for a couple of reasons. First, Pfizer used starch as an excipient, and that tended to clog up the lungs, not necessarily in terms of performance, but in terms of absorption of the insulin. The other problem was that its delivery device was large and cumbersome, a foot long and an inch wide.

Mannkind has approached the problem differently. It found a particle that stabilizes the insulin in a monomeric form. This excipient is readily removed from the lungs—it happens almost instantaneously upon touching the wet surfaces of the alveoli. The delivery device is about the same size as an ordinary police whistle. To make it function, all you have to do is inhale once.

TLSR: How is Mannkind’s stock holding up?

KM: We saw it run up over the past 6–9 months from a low of about $1.85 to well over $8, touching $9, shortly before the clinical trial news came out. Since then, the stock has backed off, partly due to concern about peripheral items related to the clinical trials. For one thing, Mannkind had designed the type 1 diabetes trial in a way that it thought might prove the superiority of Afrezza over a short-acting insulin analog, based upon the pharmacokinetic profile of the two drugs. That did not happen. Be that as it may, the trial showed a significant marketing advantage: Afrezza treatment resulted in a significantly lower level of hypoglycemic events than the short-acting insulin analog, and it lowered fasting blood glucose levels.

TLSR: What is the Mannkind’s market cap?

KM: Its market cap is $1.7 billion ($1.7B), which makes it a mid-cap stock. And the volume of trading has averaged 8.8 million (8.8M) shares per day over the last three months.

TLSR: Does it have other products on the market?

KM: Mannkind has been almost exclusively focused on developing Afrezza for more than a decade. It does have a small number of oncology drugs in very early stages of development.

TLSR: How is its cash situation?

KM: The company has adequate financing, but until it goes commercial, it is going to be burning cash. The company has some warrants that will probably be exercised, which will give it additional capital. It recently made a $160M debt-financing agreement with Deerfield, which gave the company a second $40M tranche in September. And shortly before a long-term convertible debt repayment is due in December, Mannkind will get another $40M. Upon FDA approval, it will get the fourth tranche of $40M. In the meantime, the company is working to get a partnering agreement in place. It is quite possible that such an agreement will come with upfront cash.

TLSR: Is there competition for Afrezza?

KM: The diabetes market is extremely competitive, but one thing distinguishes Afrezza from everything else available—it is an inhalable drug, which makes it convenient to use.

TLSR: Oragenics is involved with antibiotics and probiotics. What are the newest developments there?

KM: Oragenics is working behind the scenes with Intrexon Corp. (XON:NYSE), a leader in synthetic biology, to optimize the production of a natural antibiotic that bacteria use to fight each other. This particular type of antibiotic is called lantibiotic. It has a very unique molecular structure, with very novel amino acids. The collaboration has set up a production cell line and purification scheme that will be adequate for producing sufficient quantities of the lantibiotic to conduct clinical trials. That is important because lantibiotics have historically been extremely difficult, if not totally impossible, to produce in large quantities. The problem is that when you try to grow bacteria that produce a lantibiotic in culture, the lantibiotic kills the cells at concentrations so low that purifying the compound is very difficult to achieve.

TLSR: How are the market cap and stock price holding up for Oragenics?

KM: Oragenics has been doing reasonably well compared to some biotechnology companies. In the last six months, it has traded between $2.80–3.50. The company has not seen a lot of news flow recently, but it is making progress. Just recently, Oragenics reported that Intrexon has created variants of the natural lantibiotic, and that structure-activity studies will commence shortly.

TLSR: Synthetic Biologics is on the forefront of developing products to fight infection. How is its share price faring in light of its scientific prospects?

KM: Synthetic Biologics had a couple of stock price spikes during the past six months, before it settled in the $1.40–1.60 range. We are optimistic about the company for a couple of reasons. Its lead drug is a hormone called estriol (Trimesta), which is being developed for treating multiple sclerosis (MS). It is in a phase 2 trial for relapsing-remitting MS. The goal of the investigator-sponsored study is to demonstrate that Trimesta reduces the number of attacks that an MS patient encounters while on another MS drug, Copaxone (glatimer acetate injection), which is produced by Teva Pharmaceutical Industries Ltd. (TEVA:NASDAQ).

The rationale for using an estriol-based drug stems from clinical evidence that women with MS who become pregnant experience a decline in MS activity. That is, the number of lesions as measured by magnetic resonance imaging (MRI) declines as the pregnancy progresses. During the timeframe of a typical pregnancy, the level of estriol goes from virtually nothing to a very high level at the end of the third trimester. Trimesta emulates the rise that normally is seen at the start of the third trimester. We should know the results of the phase 2 trial in early 2014. At that point, assuming good results, we look forward to Synthetic Biologics entering into a licensing agreement with a large pharmaceutical company.

TLSR: What other catalysts are moving Synthetic Biologics’ share price?

KM: Synthetic Biologics has acquired a novel prophylactic agent for preventing Clostridium difficileinfections, and is moving close to a clinical trial with the compound. We believe that the company will meet with the FDA in the near future to plan a trial for H1/14, followed by the start of a phase 2 trial in H2/14.

In addition, Synthetic Biologics has two programs that are being collaboratively developed under an exclusive agreement with Intrexon Corp. One of the programs targets the bacteria that cause pertussis. The other target is a rather nasty hospital-acquired infectious agent called Acinetobacter baumannii (A. baumannii). The company is making progress in both areas. A large animal study considered a pivotal trial for the pertussis therapy, which is a monoclonal antibody, will begin toward the end of this year, and an investigational new drug (IND) enabling study of the monoclonal antibody against A. baumanniishould begin within the next six months.

TLSR: How is Synthetic’s stock faring?

KM: Remarkably, the stock has been testing its nadir during the past six months. Investors who buy Synthetic stock now should be rewarded when the Trimesta data is released.

TLSR: What is the current story on RXi Pharmaceuticals?

KM: RXi Pharmaceuticals has a presence in the small interfering RNA (siRNA) space for tissue scarring. Those RNA molecules, as you probably know, are regulatory agents found in all cells. They exist to modulate the expression of particular genes by inhibiting the translation of mRNA during protein synthesis.

RXi is looking at two different areas with very similar, if not identical, molecules targeting connective tissue growth factor (CTGF), with the goal of reducing fibrosis or scar tissue formation. CTGF works in conjunction with transforming growth factor-beta to create physiological responses associated with healing in various cells. Unfortunately, in some circumstances, this well regulated messenger system goes awry, and patients end up with dermal hypertrophic scars or keloids. In the eye, this scar formation can cause the retina to tear after surgery has been performed to reattach it, for example. The goal is to develop an anti-scarring drug for multiple applications.

More recently, RXi expanded its product portfolio by acquiring siRNA intellectual property (IP) around vascular endothelial growth factor (VEGF), which could be used in combination with the CTGF siRNA therapy for ophthalmic purposes. The company has also begun working with an academic scientist on a project that addresses retinoblastoma.

TLSR: How are its fundamentals stacking up since the last time we talked?

KM: RXi is doing very well. It has enough cash to carry it forward for at least another 12 months. Data from phase 2 clinical trials for its dermatology product should take the company comfortably to the next inflection point. We could see a nice rise in the stock over the next 12 months as the data arrives in stages.

TLSR: Thanks for your time, Keith.

KM: Thank you, and have a very nice day.

Keith Markey has been an equities analyst for more than 25 years, specializing in the biotechnology, pharmaceutical, medical device and research tools sectors. He is currently the science director for Griffin Securities Inc., an investment bank where he follows emerging healthcare companies with novel technologies. He also works with privately owned companies, helping them restructure operations, license products under development or near commercialization and raise funds from venture capital and high net-worth investors. Markey serves on the board of directors of DS Healthcare Group Inc., which specializes in products that address hair loss. Previously, he held various managerial positions in the research department of Value Line Inc., publisher of the Value Line Investment Survey and Value Line Select. Markey began his career as a biochemist, working in endocrinology and neuroscience at New York University Medical School and Weill Cornell Medical College. His research contributed to the understanding of regulatory biochemistry of the nervous system and stem cell plasticity. Markey received his doctorate in neurochemistry from the University of Connecticut and a master’s degree in business administration and finance from the Leonard N. Stern School of Business at New York University.

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

DISCLOSURE:

1) Peter Byrne conducted this interview for The Life Sciences Report and provides services to The Life Sciences Report as an independent contractor. He or his family own shares of the following companies mentioned in this interview: None.

2) The following companies mentioned in the interview are sponsors of The Life Sciences Report:Synthetic Biologics Inc., RXi Pharmaceuticals Corp. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.

3) Keith Markey: I or my family own shares of the following companies mentioned in this interview: Mannkind Corp. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: Mannkind Corp., Oragenics Inc., Synthetic Biologics Inc., RXi Pharmaceuticals Corp. Griffin Securities received investment banking fees from Intrexon Corp. within the past 12 months. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.

4) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

5) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Life Sciences Report is Copyright © 2013 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part..

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8204

Fax: (707) 981-8998

Email: [email protected]

 

 

Casey’s Marin Katusa: Conflict Could Be Good for Energy Investors

Source: JT Long of The Energy Report (9/12/13)

http://www.theenergyreport.com/pub/na/caseys-marin-katusa-conflict-could-be-good-for-energy-investors

Conflict in the Middle East has Europe scrambling to find reliable energy sources closer to home. This means investors should consider watching for a big shale discovery in a friendly location. Marin Katusa, energy expert with Casey Research, is constantly looking for the next big thing. In this interview with The Energy Report, Katusa profiles natural gas and uranium companies that could offer stable supply in a time of crisis.

The Energy Report: Energy investing is a truly global venture. What does the possibility of military action in Syria mean for energy investors?

Marin Katusa: Though Syria is not a major producer of oil, the impact of war can reach far beyond its borders. Conflict in the Middle East almost always results in higher oil prices for the rest of the world.

TER: Matt Badiali, editor of the S&A Resource Report, has said that Libya’s collapse could have a material impact on oil prices because it is a large oil producer. Do prices go up more based on actual supply disruptions or investors reacting to headlines?

MK: Prices go up for both reasons. Matt is a smart guy and a friend, and he is right about Libya. Prices are based on both actual supply and psychological factors. War results in a speculation premium, but the reality is that conflict is never good for oil production. Therefore, less production occurs, which results in higher oil prices.

TER: You recently published a primer on the history between Iran and Iraq, based on Shiite rule in both countries. How do those shifts impact oil prices in Europe and the U.S.?

MK: It impacts Europe more than the U.S. Even though the Shiites are a minority in the Middle East, there is a significant risk of a spillover effect in the Middle East, in areas like eastern Saudi Arabia. The Europeans, unfortunately, depend more on Middle Eastern oil than North America, which has developed its own natural resources. Europeans, as a result, pay more than twice as much for gas, and up to three times as much for electricity. What’s the European backup plan? Russian oil and natural gas.

In the U.S., oil and gas companies have been successful in exploiting unconventional resources, and with the success of the heavy oil from Canada, the U.S. refineries are not as dependent on oil from the Middle East compared to the Europeans.

TER: Does that mean that there are going to be more opportunities in non-Middle East oil?

MK: There will be more opportunities for U.S. oil in fields that aren’t developed yet, but the North American producers are not cheap anymore. To have a big score, investors in the resource sector want to target areas that are undeveloped. The big gains are in developing these massive resources. North America is not the only place with shale oil and gas. The key is taking positions in companies that are going to experience the large growth and development of these shale fields before consolidation by bigger companies.

TER: What about unconventional shale oil exploration? You’ve mentioned your early entry in 2007 into the shale gas sector with Cuadrilla Resources Ltd., an exploration and production company in the U.K. Is it too late to get involved in big opportunities like that?

MK: No, it’s the opposite. Cuadrilla was one of the first companies to complete a shale gas well in the U.K. Cuadrilla is a perfect example of a company that no one had heard about when we recommended it. Today, the company is trading 25x north of when we first recommended it. That success is just scratching the surface of the potential of Europe. Europe is about 10–15 years behind North America on shale development, and yet its shale formations look more promising than some of the shale formations in North America. The geology is promising, the infrastructure is already there, there is plenty of local demand and premium pricing—there are still a lot of opportunities in Europe.

TER: There have been issues with shale oil: decline rates, bottlenecked oversupplies and write-downs. How do you hedge against those sorts of risks?

MK: Bottlenecks and declines matter a lot for producers. The companies with the biggest gains from the Bakken, Marcellus shale and Eagle Ford got in early because they had an idea and proved up the concept. Those companies got bought out by bigger companies. By the time there are infrastructure bottlenecks due to production, a project has turned into a multi-well program with hundreds of wells drilled. That’s a big company problem.

That’s an issue in the Bakken because it’s been so successful. There is not enough pipeline to move the oil to the refineries, so they’ve been moving it with rail oil tankers. The industry is very entrepreneurial, and it’s solved its own problems.

Before the bottleneck issues, you have to prove up the concept and then you’re going to get the major companies that want exposure to these world-class shale formations. Cuadrilla is a case study of what is going to start happening in Europe with shale exploration.

TER: Each shale is different. The geology is different. The type of gas or oil coming out is different. How easily the product can be transported makes a difference in the price. What’s the most important of those factors?

MK: Most important for an investor is to differentiate between gas shales and oil shales. Then determine the costs to drill. Let’s take for example, the most recent results from the Chinese shale wells, which were not as promising as the Chinese hoped. They are gas shales north of 7,000 meters (7,000 m) deep. They also contain sour gas. These wells cost north of $15 million ($15M) to drill, complete and frack, and China lacks the infrastructure that the U.S. benefited from. Investors need to understand the end product. Is it dry gas? It is liquid rich? Are you in the oil formation? Are you in the vapor zone? No two shales are the same. Even in the U.S., some are naturally severely fractured, some are deep, some are oil rich and others are dry-gas rich.

You have to understand what you are investing in, what type of commodity you’re looking for, the costs and how that company is going to fund itself, because shale exploration is expensive exploration. Investors should be cautious of companies promoting moose pasture as resource-rich shale. Investors beware—homework required.

The European economy will not be able to get its act together and be competitive with Asia and North America until it lowers its energy costs. When you’re paying two to three times more for electricity and three to four times more for natural gas than your U.S. competitors, your ability to compete on a global stage is extremely compromised. Certain parts of Europe have excellent infrastructure—stay away from other parts where there is no infrastructure. Oil wells were drilled in Europe and producing before wells were drilled and producing in North America. The key is applying modern technologies that have worked in North America to old, but proven, fields that have never experienced any modern technology.

TER: Do those resources have to compete with Russia?

MK: These resources will become an alternative to Russian energy sources. Many European countries are more dependent on Russian fuel sources today than they were 20 years ago. The U.K.’s North Sea production is not what it used to be because of declining production and an increased government tax rate.

I find it ironic that European protestors are against the development of their own natural resources, yet at the same time are trying to protest Vladimir Putin’s energy agendas. Europe’s lack of developed resources is exactly what keeps the continent dependent on Russian natural resources.

TER: What about North America? Are you as optimistic about the opportunities there?

MK: Definitely. Mexico has become a major importer of U.S. natural gas. Petróleos Mexicanos (PEMEX), the national oil company in Mexico, has seen a significant decrease in production because it has spent its profits funding social programs rather than reinvesting them into the oil and gas fields. Now it needs to import from the U.S. In the next five years, Mexico could open up to foreign companies. It’s going to be something we’re watching very closely. It’s definitely something investors will want to keep on their radar as the Eagle Ford extends into Mexico.

In North America, and Canada specifically, a hot story is companies profiting from West Coast liquefied natural gas (LNG). The oil sands are a very exciting story, as is further development of the shale fields in North America. But you’re not going to get the big upside in North America because developing and producing these shale formations after they’ve been discovered is no longer in the cards for a small company. It’s just too capital intensive. The biggest upside for a small company is getting the real estate before anyone else recognizes it and attracting the majors’ large pocketbooks to develop those fields. Junior companies can’t develop oil sands. It’s too expensive. LNG is a big-company game. And you’re not going to get a 10 bagger with these big oil companies.

TER: What about oil services?

MK: It’s the same story. We’ve had a great run recently with Halliburton Co. (HAL:NYSE), Trican Well Service Ltd. (TCW:TSX) and Calfrac Well Services Ltd. (CFW:TSX). They will benefit from the development of these North American shale fields. We were surprised how well Halliburton did because it’s the world’s second-largest service company, but you’re not going to get the multibagger potential out of these companies. They will pay decent yields, nothing extravagant.

TER: You and Rick Rule have talked a lot about the inevitability of a uranium renaissance, but prices have actually come down since the beginning of the year. In May, you moderated a webinar that pointed to increased demand and decreased supply due to a shift in leadership in Japan on the demand side and the end of the Russian program pumping converted nuclear fuel into the market on the supply side. Are you still predicting price increases for uranium?

MK: I’m very bullish. Since our webinar, of the Top 3 companies that we presented, one is up 65% in this market and another had a 100% gain. That said, we are starting to see more companies announce lower production and delayed production due to the low prices of uranium. The cure for low prices is low prices, and we are starting to see that.

There is still hesitation in the market because of the tragedy at Fukushima and radiation that continues to leak into the water. Japan has had to slow down bringing nuclear reactors back online.

What has really changed long term? Nothing. The trends driving the market are still in place. Growth in China will continue. Investors should be invested in either the highest-grade deposits, which are in the Athabasca Basin in Canada, or the lowest-cost producers, such as the ones that have in situ recovery (ISR) production in the U.S.

If you focus on ISR in the U.S., you want to be exposed to warmer ISR production. It’s about 25–30% cheaper to produce with this method because they don’t need to insulate the wells. Whenever you’re moving water, you don’t want to be around cold temperatures because freezing occurs.

Stay away from companies that have large debt loads they incurred before Fukushima; that is crippling to a company. The low-grade, conventional producers, such as Paladin Energy Ltd. (PDN:TSX; PDN:ASX), are suffering from low spot uranium prices and debt. We’ve always stayed away from companies like that. Uranium Energy Corp. (UEC:NYSE.MKT) has actually increased in price since our webinar because it is a low-cost, shallow ISR producer that aligned itself with the price of the commodity. If uranium goes up, it can produce more uranium from its ISR wells, but if the price goes down, it is not depleting its reserves by producing at a low price.

With conventional uranium production, the fixed costs of running the mine are much higher. They can’t just shut down like an ISR operation, which is more like an oil or gas well where you can increase and decrease the production.

At the same time, the U.S. Energy Information Administration (EIA) recently came out with a report showing that the long-term dependency on uranium for North America is still there. With Asia developing its diversified energy matrix, countries like Korea, China and even Japan will have uranium demand. Japan’s electricity costs are crippling its economy. It is paying north of $16/thousand cubic feet ($16/Mcf) where in Canada they’re paying less than $3/Mcf. Even with all the horrible news coming out in the aftermath of the Fukushima disaster, Japan will bring on its nuclear reactors—not on the timeframe uranium investors would like, but it will happen.

TER: Do you focus on the spot price or the long-term price?

MK: I focus more on the long-term price because more than 90% of the uranium traded globally is based on the long-term price. The spot price, which everybody is so worried about, makes up between 5–8% of the uranium traded. That’s irrelevant. Even in a decreasing uranium market, you’re looking at prices north of 40% higher for the long-term price—very bullish for uranium long term.

It’s funny because the oil markets are currently in backwardation, meaning that future oil prices are lower than current prices, and the opposite is true for uranium, yet the investors are avoiding the uranium sector like the plague. They will eventually come back, and at that time, you will want to sell your stocks. Uranium is a perfect contrarian investment right now.

TER: You mentioned Uranium Energy Corp. Are there any catalysts for that company coming up?

MK: President Amir Adnani has positioned Uranium Energy to maintain its strong balance sheet in this near-term tough market by decreasing the production at its Palangana mine, while advancing Goliad toward production this fiscal year and advancing the large Burke Hollow ISR project towards production. The company trades at a discount to its net asset value (NAV), and Uranium Energy is positioning itself well for when uranium prices do recover. Over the years, I’ve watched Uranium Energy go from exploration to production. Palangana was proof that the hub-and-spoke strategy works. Once Goliad comes on-line, the big cash flows will start for the company. Uranium Energy is a low-cost producer. One in 3,000 exploration projects ever becomes a mine, so the company has already beat that hurdle. More important for me is that Uranium Energy is doing all this while preserving a strong balance sheet. Other companies have not positioned themselves to be able to keep a strong balance sheet. I’d expect Uranium Energy will probably do some major acquisitions within the next 12 months.

The president of the company, Amir Adnani, who is on the Casey NexTen List, has positioned the company to benefit from a weak market. That’s the type of company that we want to be invested in—strong balance sheet, strong management team and always looking to grow the company. When the spot price does catch up to the long-term price and the long-term price increases because of the growing demand, Uranium Energy will be able to increase production because it has already developed its assets.

I believe that within 10 years, just like the oil market has a WTI and Brent pricing, there will be a divergence in the uranium price between the east and the west. No one has ever talked about this.

With the highly enriched uranium (HEU) agreement ending at the end of this year, there is going to be a transition agreement, which everyone knows is already going to cost more for the Americans than the HEU agreement. When the Asians, Saudi Arabia and the Middle East do develop reactors, the Russians will start signing deals with them and there will be a divergence. The U.S. producers of uranium will get a premium because it’s a safe, local, domestic, strategic supply of fuel.

In the early 1960s, the U.S. produced more than 30 million pounds (30Mlb). It was the No. 1 producer of uranium in the world. Last year, it produced less than 3.5 Mlb. Yet, it has increased its consumption of uranium during that time. Here’s a real ironic result of the cold war: American producers produce less uranium on American soil than Russians produce on American soil. The Russians bought a company called Uranium One, which produces more uranium in the U.S. than all U.S. uranium producers combined. Eventually the market will catch up to itself, and you want to be positioned with U.S., low-cost producers that are able to adjust their production to optimize their cash flows depending on the spot price and the long-term price of uranium.

In two to five years, there should be significantly higher uranium prices. Remember when Doug Casey and Rick Rule first started talking heavily about uranium in 1998? The uranium bull market didn’t start until about 2004. Things always take longer than people want them to, but they can go a lot higher than you can expect, too. Investors want to be positioned with the right companies that will survive this downturn.

TER: What other uranium company do you like?

MK: Uranium Participation Corp. (U:TSX). It’s actually the lowest-risk way to invest in uranium. It has no production risk. It has no exploration risk. It has no management risk. It has no political or environmental risks. Uranium Participation Corp. (U:TSX) is essentially a holding company for U3O8 uranium and UF6 uranium hexafluoride. It’s probably the only way retail investors can have exposure to UF6, which I’m also very bullish on. The company’s NAV is split pretty evenly between U3O8 and UF6. It has the uranium in a storage warehouse that’s insured and bonded. We’ve had a lot of e-mails come in that say, “Well, what happens if someone comes in and steals the uranium?” That would actually be an ideal situation because then the insurance companies would have to replace the stolen uranium, and because the company trades at a discount to its NAV, investors would get a boost from that unrealistic event.

TER: You’re going to be speaking, along with Ron Paul and Doug Casey, at the Casey Research 2013 Summit in October in Arizona. What’s the message you’re going to be sharing there?

MK: I’ve put together an energy panel with the former energy secretary of the U.S., the former energy minister of Canada, the U.K. authority on nuclear energy and the Middle East, Keith Hill with Africa Oil Corp (AOI:TSX.V) and Nolan Watson from Sandstorm Metals and Energy Ltd. (SND:TSX.V). The panel, which I’ll be moderating with these industry heavyweights, is going to be focused on oil, natural gas, uranium and coal.

TER: Do you have any final advice for how in the midst of possible war in multiple hotspots, energy investors can position themselves defensively, or be optimized for what could be coming?

MK: I think investors have to focus on the political risks. This will sound horrible from a moral standpoint, but conflict in the Middle East will be good for investors exposed to oil if they understand the political risks. If we have more conflicts in the Middle East, there is one sure result: higher oil prices. That is good for the energy investor. To position yourself best, you want to invest in companies that have a strong management team, a strong balance sheet and that are in areas that are most affected by the conflicts and higher oil prices. Do you want to be invested in a company producing oil in Egypt with all this conflict potential? No, you don’t. Do you want to be invested in a company that is exploring for oil in Europe? I have, and I think you should too.

TER: Thank you very much for taking the time to talk to us.

MK: My pleasure.

With a background in mathematics, Marin Katusa left teaching post-secondary mathematics to pursue portfolio management within the resource sector. He is regularly interviewed on national and local television channels in North America such as the Business News Network (BNN) and many other radio and newspaper outlets for his opinions and insights regarding the resource sector. Katusa is the chief investment strategist for the energy division of Casey Research. He is the editor of the Casey Energy Report, Casey Energy Confidential and Casey Energy Dividends newsletters. A regular part of his due diligence process for Casey Research includes property tours, which has resulted in him visiting hundreds of mining and energy producing and exploration projects all around the world. For more information about the Casey Research 2013 Summit, October 4, 5 and 6 in Tucson, Arizona, visit theCasey Research 2013 Summit.

Want to read more Energy Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Interviews page.

DISCLOSURE:

1) JT Long conducted this interview for The Energy Report and provides services to The Energy Reportas an employee. She or her family owns shares of the following companies mentioned in this interview: None.

2) The following companies mentioned in the interview are sponsors of The Energy Report: None. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.

3) Marin Katusa: I or my family own shares of the following companies mentioned in this interview: Uranium Participation Corp and Uranium Energy Corp. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.

4) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

5) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Energy Report is Copyright © 2013 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Energy Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8204

Fax: (707) 981-8998

Email: [email protected]

 

 

Indonesia raises rate 25 bps, 4th hike this year

By www.CentralBankNews.info     Indonesia’s central bank raised its benchmark BI rate by 25 basis points to 7.25 percent, it’s fourth rate rise this year, and revised downward its growth forecasts for this year and 2014 while taking note of lower inflationary pressures in August.
    In addition to the BI rate, Bank Indonesia (BI) also raised the rate on its standing facility by 25 basis points to 7.25 percent and the rate on its deposit facility to 5.50 percent from 5.25 percent.
    “The action forms part of the follow-up measures taken to reinforce the policy mix instituted by Bank Indonesia, which focuses on controlling inflation, stabilising the rupiah exchange rate and ensuring the current account deficit is managed to a sustainable level,” the central bank said.
    The central bank has now raised rates by 150 basis points this year to help stem the pressure on the rupiah exchange rate and the BI said it would continue to stabilise the currency, underpinned by efforts to strengthen monetary operations and deepen the foreign exchange market.
    “Bank Indonesia is of the opinion that the aforementioned policies, accompanied by the array of policies implemented previously, will expedite reductions in the current account deficit and bring the rate of inflation down to its target corridor of 4.5 percent, plus/minus 1 percentage point, in 2014,” the central bank said.

    Last month the BI signed a $12 billion swap agreement with the Bank of Japan to bolster its defenses and on Monday the finance minister said Indonesia was seeking further bilateral swap agreements that would allow it to access more than $30 billion from new and existing swap lines. A government official also said Indonesia may extend a 2009 swap agreement with China.
      “Bank Indonesia predicts that the global economic slowdown and financial uncertainty will persist,” the bank said, due to “lukewarm growth” in emerging markets, especially India and China.
     The central bank cut its 2013 growth forecast to 5.5-5.9 percent from a previous forecast of 5.8-6.2 percent, and the 2014 growth forecast to 5.8-6.2 percent from a previous 6.0-6.4 percent due to the weaker global economic outlook.
    The country’s balance of payments is forecast to improve after a large trade deficit in July from large-scale imports of oil and gas during the religious holidays boosted the current account deficit. But the current account deficit should fall as these imports normalize, domestic demand weakens and other import-limiting policies take effect.
   The central bank said the private foreign debt position was viewed as “relatively sound” and foreign exchange reserves at the end of August were US$ 93.0 billion, stable from July’s $92.7 billion.
    Indonesia’s rupiah depreciated gradually through the first months of the year and then started to drop sharply in early July.
    “Up to the end of August 2013, dogged pressures on the rupiah persisted,” the BI said, noting that the rupiah closed at 10,920 to the U.S. dollar, down 5.8 percent from the end of July and 11.7 percent compared with the end of 2012. During September the rupiah continued to fall, quoted at 11,350 – 11,515 per dollar on Sept. 11.
    “Bank Indonesia will continue to run the necessary means to stabilize the rupiah exchange rate,” the BI said.
    Inflationary pressures eased in August, with prices up 1.12 percent in August, for an annual rate of 8.79 percent, compared with a monthly rise of 3.29 percent in July, for annual inflation of 8.61 percent.
     “Bank Indonesia expects inflationary pressures to continue to dissipate, with a low level of inflation predicted in September 2013,” the BI said.
    The BI forecasts average inflation this year in a range of 9.0-9.8 percent and then ease to its target range in 2014.
   In the second quarter, Indonesia’s Gross Domestic Product rose by 2.61 percent for annual growth of 5.81 percent, the lowest rate since the third quarter of 2011, and down from 6.03 percent in the first quarter.
    On Wednesday the central bank’s deputy governor told Reuters that inflation would ease significantly in September following a spike after an average 33 percent increase in fuel prices at the end of June.

    www.CentralBankNews.info
   

Philippines holds rates steady, risk to inflation from oil

By www.CentralBankNews.info     The Central Bank of the Philippines (BSP) held its policy rates steady, including the benchmark overnight borrowing rate at 3.50 percent, in light of a “benign inflation environment” but added that the balance of risks to the inflation outlook had shifted slightly to the upside due to volatile oil prices from geopolitical tensions in the Middle East.
    The BSP, which has held its benchmark rate steady since October 2012, said the latest forecasts still show that the future path of inflation is broadly in line with the central bank’s 2013, 2014 target range of 4.0 percent, plus/minus 1.0 percentage point, and the 2015 range of 3.0 percent, plus/minus 1 percentage point.
    Despite the slightly higher risk to inflation from volatile oil prices, the BSP said world economic prospects remain subdued “thus tempering pressures on global commodity prices.”
    The central bank’s decision was widely expected after the governor, Amando Tetangco, said earlier today that he saw no urgency to change the policy stance as the inflation outlook remains benign.

    The headline inflation rate in the Philippines eased to 2.1 percent in August from July’s 2.5 percent, the lowest since October 2009, and within the BSP’s forecast of 1.9-2.7 percent. The year-to-date inflation rate is at 2.8 percent.

    “Domestic economic activity has also been growing at a solid pace, supported by firm demand and buoyant business sentiment,” the BSP said, adding robust lending to the productive sectors in the economy should also help moderate price pressures.
    The central bank’s recent adjustments of its Special Deposit Account facility contributed to a rise in domestic liquidity (M3) growth in July.
    “As M3 growth rats are expected to decline once these adjustments have been completed, a temporary period of strong M3 growth is not expected to lead to significant inflationary pressure,” the central bank said.
    The Philippine economy expanded by 1.4 percent in the second quarter from the first for annual growth of 7.5 percent, slightly down from the first quarter’s 7.7 percent.
    

   

The Rundown on Runaway Inflation in One Chart

Despite a dramatic increase in the Fed’s balance sheet, the Producer and Consumer Price Indexes are subdued

By Elliott Wave International

Famed radio broadcaster Earl Nightingale, who was the voice of Sky King on the radio and later went on to become a motivational speaker, described what he believed to be the biggest sin a public speaker could commit.

It’s not stumbling over words or going overboard with warm-up jokes or speaking too long. The greatest sin a public speaker can commit is to be uninteresting. What’s more, the failure is related much more to the speaker’s lack of preparation than to the topic. Nightingale argued that even the history of the fork could become an interesting talk.

We believe our economic analysis is made even more interesting and insightful by using our own unique charts. They reflect our independent analysis, and they are different from what you find in other financial publications.

Robert Prechter created this chart for a speech he gave to the Market Technicians Association in April 2013, which is reprinted in the July-August Elliott Wave Theorist. He used the chart to address the often-voiced fear that runaway inflation is just around the corner because, via quantitative easing, the Federal Reserve has been manufacturing new banknotes and swapping them for the debts of others – a process that inflates the supply of dollars.

The Fed has been inflating the supply of dollars at a stunning 33% annual rate over the past five years. It plans to continue doing so at least through the end of this year and has kept open the possibility that it will do so indefinitely. This is the policy upon which those predicting runaway inflation are basing their arguments. With this dramatic a rise, it’s no wonder investors expect inflation and have aggressively positioned for it.

Look just about anywhere else, however, and you will see subtle evidence of deflationary pressures. Given knowledge only of the Fed’s inflating, many people would expect the Producer and Consumer Price Indexes to be rising at a rate of 33% annually. But, as you can see in [the chart], the PPI’s annual rate of change is stuck at zero and the CPI has been rising at only a 2% rate.

The Elliott Wave Theorist, July-August 2013

Everyone else is talking about inflation, but deflation is the real threat they should be concerned with. Our friends at Elliott Wave International have created a report that spells out the dangers of deflation and you can have it on your screen with just a few clicks — free! See below for full details.

 


Learn Why Deflation Is the Biggest Threat to Your Money Right Now

Discover Robert Prechter’s views on the unfolding deflationary trend by reading the 90-page report, The Guide to Understanding Deflation. This guide will help you survive a major deflationary trend, and even equip you to prosper.

Plan and prepare for your financial future. Download Your Free 90-Page Deflation Survival Guide eBook >>

This article was syndicated by Elliott Wave International and was originally published under the headline The Rundown on Runaway Inflation in One Chart. EWI is the world’s largest market forecasting firm. Its staff of full-time analysts led by Chartered Market Technician Robert Prechter provides 24-hour-a-day market analysis to institutional and private investors around the world.

 

Gold Hits 1-Month Low Pre-Fed, Asian Stockpiles Cut Bar Demand Outlook in Half

London Gold Market Report
from Adrian Ash
BullionVault
Thurs 12 Sept 08:30 EST

LONDON PRICES for wholesale gold slipped to 1-month lows at $1334 per ounce Thursday lunchtime, extending an early $20 slump in what one dealer called “anaemic trade”.

European stock markets reversed morning losses, and crude oil rallied, as the US and Russian foreign ministers met in Switzerland to discuss Syria’s chemical weapons.

Gold priced in Sterling fell to a 5-week low beneath £846 as the British Pound held near 7-month highs on the currency market.

 Silver meantime dipped below $22.50 per ounce, down almost 6% for the week so far.

 “Gold’s massive trading volumes in mid-year will now dwindle,” says the latest Gold Survey Update from Thomson Reuters GFMS, because inventories amongst the world’s heaviest consumer nations are already “generally heightened” following the surge in re-stocking during 2013’s price crash.

 “India is the exception, [because] changes in import and distribution rules have meant that inventories generally are low, while smuggling is on the increase,” says the report.

 Overall, and even with the world’s former No.1 consumer being eclipsed by China in 2013, GFMS is now expecting “a tangible contraction” in jewelry fabrication and perhaps a 50% drop in gold bar demand worldwide during the second-half of the year.

 For professional investors, and “as geopolitical risks fade,” Bloomberg quotes chief investment strategist Wang Xiaoli at CITICS Futures, China’s largest brokerage by market value, “the focus is shifting back to QE and the Fed meeting next week.

 “We expect the market to remain volatile till then.”

 With the US Fed widely expected to start tapering its quantitative easing program next week, “The one thing I would say is that we should expect volatility,” agrees Peter Sands, CEO of Standard Chartered Bank, speaking to CNBC at the World Economic Forum in Dalian, China.

 “When you have that degree of intervention, stopping it is not going to be a smooth and simple process.”

 “I don’t see a short-term crisis in emerging Asia,” said IMF deputy director general Zhu Min at the same conference, noting concerns over the impact of Fed tapering on developing economies.

 Credit ratings agency Moody’s today warned that the plunging Rupee, widely blamed on the approach of Fed tapering, would hurt the ability of Indian companies to borrow.

 “The situation is very different from 1997,” Zhu countered. “[But] if a country has payment problems, our job is to maintain global financial stability.”

 “The gold market is expecting tapering next week from the Fed,” said Bank of America Merrill Lynch metals strategist Michael Widmer in an interview Wednesday.

 “If the Fed delays or doesn’t do it all, gold could rally.”

 But longer-term, real interest rates are rising, says Widmer, and inflation expectations are low.

 “So why hold gold? I would sell into that rally.”

 Writing late Wednesday, the “short-term uptrend line [in gold] could be taken out if prices dip below $1350,” said analyst Edward Meir at brokers INTL FC Stone.

 “In addition, downside bets seem to be increasing” on the gold futures and options market.

 Data on speculative gold contracts last week showed hedge funds and other non-industry players cutting their bearish bets by 60% from July’s 13-year peak.

 The number of bullish bets held by speculative traders in US gold futures and options rose only 11% over those two months, however.

 “We would read any tapering of less than $10bn per month as bullish relative to where gold is now,” said South Africa’s Standard Bank in a note Wednesday, “while tapering of more than $15bn would [be] bearish.”

 Cutting the Fed’s $85 billion in monthly QE “may weigh on gold,” agrees bullion market maker HSBC. But “an emphasis by the Fed to keep [its short-term interest] rate low may help off-set some of bullion’s potential losses.”

Adrian Ash

BullionVault

Gold price chart, no delay | Buy gold online

 

Adrian Ash is head of research at BullionVault, the secure, low-cost gold and silver market for private investors online, where you can buy gold and silver in Zurich or Singapore for just 0.5% commission.

 

(c) BullionVault 2013

Please Note: This article is to inform your thinking, not lead it. Only you can decide the best place for your money, and any decision you make will put your money at risk. Information or data included here may have already been overtaken by events – and must be verified elsewhere – should you choose to act on it.

 

Facebook Shares Climbs To Its Highest Since 2012

By HY Markets Forex Blog

Facebook Shares, edged up more than 3%, beating its previous record of $45 in May 2012. The largest social network is valued at $106 billion, as investors focus on the new mobile advertising gains and potential to increase its ad revenue.

The social network’s stock rose 3.3% to $45.05.

On Wednesday, the Chief Executive of Facebook, Mark Zuckerberg spoke at the technology conference in San Francisco and said the IPO process had assisted the social network to grow stronger.

“Having gone through what I think most people would characterize as an extremely turbulent first year as a public company, I can tell you I actually don’t think it’s that bad,” said Zuckerberg.

Investors have reacted positively towards the company’s improved stock figures and the company’s efforts to improve its mobile advertising revenue as it rose by 75% in the second quarter, as it reached analysts estimates.

Facebook Shares –  Facebook Previous fall & estimates

Facebook have previously lost its value when it made its stock debut on the Nasdaq exchange in May, 2012, In which the company traded at $38 per share. The company has made efforts to improve and grow its revenue by expanding its mobile advertising, which have attracted more users and investors.

The company’s shares have advanced 60% higher since July with a better-than-expected earnings reported.

Facebook said it’s expecting its mobile advertising to exceed revenues from desktop ads, the mobile advertising made up 41% of its total revenue.

 

To find out more on our product offerings, visit www.hymarkets.com and start trading today with only $50!

The post Facebook Shares Climbs To Its Highest Since 2012 appeared first on | HY Markets Official blog.

Article provided by HY Markets Forex Blog

Gold Prices Drops Ahead Of FOMC Meeting

By HY Markets Forex Blog

Gold prices were seen falling on Thursday, dropping to its lowest level in three weeks, as investors worries on whether the Federal Reserve (Fed) will begin to scale-back on its bond-buying program earlier than expected.

Gold futures edged 1.14% lower to $1,347.60 an ounce at the time of writing, while silver dropped 1.50% to $22.835 an ounce. The US dollar index declined 0.09% to 81.4430.

On Wednesday, holdings in the world’s largest gold-backed exchange-traded fund SPDR Gold Trust remained unchanged at 917.13 tonnes..

Gold Prices – Fed Scale-back worries

The fall in gold price, which dropped to 19% this year, was due to the continuous worries over whether the Federal Reserve (fed) would begin to taper its bond-buying program earlier than expected if the world’s largest economy shows an improvement. Analysts are expecting the Fed to announce when it will begin to scale-back on its stimulus program in its next meeting on September 17-18.

“The September FOMC meeting, where our economists expect a tapering could prove the catalyst to push gold prices lower although the looming debt ceiling may initially limit the downside to gold prices until it is raised by the end of October,” analysts at Goldman Sachs wrote in a research report.

The US weekly unemployment figures are expected to increase by 330,000 in the week ending September 7, up from previous record of 323,000 last week.

The Gold market has an influence with what happens on the US labour market, which is also linked to the central bank’s policy.

Syria Tension

Investors are still focused on the situation in Syria after the US President Barack Obama asked the Congress to push back the vote over the US military intervention in Syria, after the country agreed to accept Russia’s proposal to give up its chemical weapons under international control.

The US Secretary of State Job Kerry is expected to meet the Russian Foreign Minister Sergei Lavrov later in the day to discuss plans for Syria.

Gold Prices – Global demand

Bullion global demand is expected to fall to 2,237 tonnes in the second half of the year, compared to previous year’s record of 2,309 tonnes, according to Thomson Reuters GFMS.

 

Visit www.hymarkets.com and start trading Metals online  today from only $50!

The post Gold Prices Drops Ahead Of FOMC Meeting appeared first on | HY Markets Official blog.

Article provided by HY Markets Forex Blog

Elliott Waves and Fibonacci Suggest a Coming Bearish Reversal on Pound (Forex: GBPUSD)

Pound (Forex: GBPUSD) is in bullish mode and reached our projected zone for this week; 1.5800-1.5900 which is actually a very important resistance zone in combination with the wave principle and Fibonacci levels. As you can see on the chart we are tracking a huge wedge pattern called an ending diagonal which usually predicts a very strong reversal. With that said, we are keeping an eye on potential sell-off on this pair from current resistance zone. This sell-off can happen soon if we consider that prices are in late stages of wave 5) now, testing 61.8% Fibonacci projection compare to wave 3) and also approaching 161.8 % extension of wave 4).

However as always only price can confirm the direction you anticipate. In other words, we need a five wave decline from the highs to confirm further bearish waves for the pair. Only then trader could be interested in short opportunities, until then stay aside.

GBPUSD 4h Elliott Wave Analysis GBPUSD 4h Elliott Wave Analysis

Written by www.ew-forecast.com | Try EW-Forecast.com’s Services Free For 7 Days at http://www.ew-forecast.com/service